U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H17FN4O3
Molecular Weight 308.3082
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DELPAZOLID

SMILES

CN1CCN(C=N1)C2=C(F)C=C(C=C2)N3C[C@H](CO)OC3=O

InChI

InChIKey=QLUWQAFDTNAYPN-LLVKDONJSA-N
InChI=1S/C14H17FN4O3/c1-17-4-5-18(9-16-17)13-3-2-10(6-12(13)15)19-7-11(8-20)22-14(19)21/h2-3,6,9,11,20H,4-5,7-8H2,1H3/t11-/m1/s1

HIDE SMILES / InChI

Molecular Formula C14H17FN4O3
Molecular Weight 308.3082
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

LCB01-0371, an oxazolidinone derivative, shows good activity against Gram-positive pathogens, including Staphylococcus aureus. It is also effective against multidrug-resistant tuberculosis and is currently under clinical development.

Approval Year

PubMed

PubMed

TitleDatePubMed
In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
2010 Dec
Patents
Substance Class Chemical
Created
by admin
on Sat Dec 16 09:42:25 GMT 2023
Edited
by admin
on Sat Dec 16 09:42:25 GMT 2023
Record UNII
43EP6XV33E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DELPAZOLID
INN  
INN  
Official Name English
LCB-01-0371
Code English
(5R)-3-(3-FLUORO-4-(1-METHYL-5,6-DIHYDRO-1,2,4-TRIAZIN-4(1H)-YL)PHENYL)-5-(HYDROXYMETHYL)-1,3-OXAZOLIDIN-2-ONE
Systematic Name English
Delpazolid [WHO-DD]
Common Name English
LCB-010371
Code English
delpazolid [INN]
Common Name English
LCB01-0371
Common Name English
2-OXAZOLIDINONE, 3-(4-(5,6-DIHYDRO-1-METHYL-1,2,4-TRIAZIN-4(1H)-YL)-3-FLUOROPHENYL)-5-(HYDROXYMETHYL)-, (5R)-
Systematic Name English
(5R)-3-(3-FLUORO-4-(1-METHYL-5,6-DIHYDRO-1,2,4-TRIAZIN-4-YL)PHENYL)-5-(HYDROXYMETHYL)OXAZOLIDIN-2-ONE
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 590317
Created by admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
Code System Code Type Description
CAS
1219707-39-7
Created by admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
PRIMARY
FDA UNII
43EP6XV33E
Created by admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
PRIMARY
NCI_THESAURUS
C166717
Created by admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
PRIMARY
DRUG BANK
DB13077
Created by admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
PRIMARY
SMS_ID
300000034072
Created by admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
PRIMARY
INN
10479
Created by admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
PRIMARY
PUBCHEM
44205191
Created by admin on Sat Dec 16 09:42:25 GMT 2023 , Edited by admin on Sat Dec 16 09:42:25 GMT 2023
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
MBC99
TARGET ORGANISM->INHIBITOR
Resistant rate of MDR-TB = 0.8%
MIC90
TARGET ORGANISM->INHIBITOR
MIC
TARGET ORGANISM->INHIBITOR
Resistant rate of MDR-TB = 4.2%
MIC90
TARGET ORGANISM->INHIBITOR
A broad spectrum antibiotic.In phase I clinical trials, found to have better safety (milder side effects) than LZD due to its more rapid clearance,88 although final results from a phase IIa EBA study may suggest lower efficacy than both LZD and sutezolid.
Related Record Type Details
ACTIVE MOIETY